Capivasertib-Induced Diabetic Ketoacidosis in a Patient With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Metastatic Breast Cancer and No Prior History of Diabetes Mellitus: A Case Report

Authors

Yoan E. Rodriguez, HCA HealthcareFollow
Rishu Batra, HCA HealthcareFollow
Kunal Patel, HCA HealthcareFollow
Suzanne Martinez, HCA HealthcareFollow

Division

South Atlantic

Hospital

Orange Park Medical Center

Document Type

Case Report

Publication Date

7-2-2024

Keywords

akt inhibitor's adverse effect, breast cancer, capivasertib, diabetic ketoacidosis (dka), er+/her2- metastatic breast cancer

Disciplines

Endocrine System Diseases | Internal Medicine | Medicine and Health Sciences | Neoplasms

Abstract

Capivasertib, a pan-AKT inhibitor, has shown promising efficacy in treating metastatic tumors harboring the AKT1 E17K mutation. However, its use is associated with notable adverse events, including hyperglycemia, which may impact treatment outcomes. This case describes a patient with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer and no prior history of diabetes who developed diabetic ketoacidosis (DKA) following capivasertib therapy.

Publisher or Conference

Cureus

Recommended Citation

Rodriguez YE, Batra R, Patel K, Martinez S. Capivasertib-Induced Diabetic Ketoacidosis in a Patient With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Metastatic Breast Cancer and No Prior History of Diabetes Mellitus: A Case Report. Cureus. 2024;16(7):e63710. doi:10.7759/cureus.63710